A rat study reports that grid-shaped radiation boosts CD19-directed CAR T cell efficacy in brain lymphoma, preserving survival compared with conventional radiotherapy approaches. Separately, a pharmacovigilance analysis of nearly five million adverse-event reports suggests liver injury after CAR T-cell therapy is predominantly early and associated with cytokine release syndrome—while still flagging a persistent signal independent of CRS in idecabtagene vicleucel that merits prospective confirmation. Together, the results reinforce a dual need: better selection of radiation modalities in CAR T combination regimens and closer temporal attribution of organ toxicity during safety monitoring.